HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a $7 price target.
July 19, 2023 | 10:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Unicycive Therapeutics (NASDAQ:UNCY) has had its 'Buy' rating reiterated and $7 price target maintained by HC Wainwright & Co.
The reiteration of a 'Buy' rating and maintenance of a $7 price target by HC Wainwright & Co. is a positive signal for Unicycive Therapeutics. This could potentially lead to increased investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100